CUE insider transaction filings
Cue Biopharma, Inc. — 39 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-17. Screen CUE transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-17 | 4 | Ray Sumita — Chief Legal Compliance Officer | Option exercise (M): 18,196 @ $0 · Sale (S): 2,383 @ $29.37 · Sale (S): 6,442 @ $30.35 · Sale (S): 4 @ $31.13 · Option exercise (M): 18,196 (derivative) @ $0 | EDGAR |
| 2026-08-17 | 4 | Meluzio Michael Vincent — VP, Prin. Accounting Officer | Option exercise (M): 13,647 @ $0 · Sale (S): 1,519 @ $29.37 · Sale (S): 4,106 @ $30.35 · Sale (S): 3 @ $31.13 · Option exercise (M): 13,647 (derivative) @ $0 | EDGAR |
| 2026-08-14 | 4 | Lin Shao-Lee — Chief Executive Officer, Director | Option exercise (M): 109,179 @ $0 · Sale (S): 34,225 @ $26.99 · Sale (S): 5,775 @ $27.75 · Sale (S): 5,423 @ $27.19 · Sale (S): 2,375 @ $28.11 · Sale (S): 10,460 @ $29.48 · +1 more | EDGAR |
| 2026-08-03 | 4 | Ahlers James M — Chief Financial Officer | Grant/award (A): 25,500 @ $0 · Grant/award (A): 51,000 (derivative) @ $0 | EDGAR |
| 2026-07-30 | 4/A | Lin Shao-Lee — Chief Executive Officer, Director | Grant/award (A): 90,906 (derivative) @ $11 · Grant/award (A): 45,453 (derivative) | EDGAR |
| 2026-07-15 | 4 | Borie Dominique Christian — Chief Medical Officer | Grant/award (A): 31,500 @ $0 · Grant/award (A): 63,000 (derivative) @ $0 | EDGAR |
| 2026-07-10 | 4 | Meluzio Michael Vincent — VP, Prin. Accounting Officer | Grant/award (A): 40,942 @ $0 · Grant/award (A): 40,942 (derivative) @ $0 | EDGAR |
| 2026-07-10 | 4 | Meehan Viola Mong — Director | Grant/award (A): 21,800 @ $0 | EDGAR |
| 2026-07-10 | 4 | Sarraf Pasha — Director | Grant/award (A): 21,800 @ $0 | EDGAR |
| 2026-07-10 | 4 | Garzone Pamela — Director | Grant/award (A): 21,800 @ $0 | EDGAR |
| 2026-07-10 | 4 | Camardo Daniel A. — Director | Grant/award (A): 21,800 @ $0 | EDGAR |
| 2026-07-10 | 4 | Lin Shao-Lee — Chief Executive Officer, Director | Grant/award (A): 327,537 @ $0 · Grant/award (A): 327,537 (derivative) @ $0 | EDGAR |
| 2026-07-10 | 4 | Ray Sumita — Chief Legal Compliance Officer | Grant/award (A): 54,589 @ $0 · Grant/award (A): 54,589 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | Camardo Daniel A. — Director | Grant/award (A): 1,626 (derivative) @ $0 | EDGAR |
| 2026-06-03 | 4 | Lin Shao-Lee — Chief Executive Officer, Director | Purchase (P): 90,906 (derivative) @ $11 · Purchase (P): 45,453 (derivative) | EDGAR |
| 2026-06-02 | 4 | Meehan Viola Mong — Director | Grant/award (A): 1,626 (derivative) @ $0 | EDGAR |
| 2026-05-07 | 4 | Lin Shao-Lee — CHIEF EXECUTIVE OFFICER, Director | Grant/award (A): 327,537 @ $0 · Grant/award (A): 655,074 (derivative) @ $0 | EDGAR |
| 2026-04-10 | 4 | Sandercock Colin — SVP, GENERAL COUNSEL | Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2026-04-10 | 4 | Warren Lucinda — CHIEF BUSINESS OFFICER | Grant/award (A): 250,000 (derivative) @ $0 | EDGAR |
| 2026-04-10 | 4 | Baker Daniel G. — CHIEF DEVELOPMENT OFFICER | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Morich Frank — Director | Grant/award (A): 24,400 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Garzone Pamela — Director | Grant/award (A): 24,400 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Verheyen Patrick — Director | Grant/award (A): 24,400 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Sarraf Pasha — Director | Grant/award (A): 24,400 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Kiener Peter A — Director | Grant/award (A): 24,400 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Broadfoot Jill Marie — Director | Grant/award (A): 24,400 (derivative) @ $0 | EDGAR |
| 2026-01-02 | 4 | Sarraf Pasha — Director | Purchase (P): 4,229 @ $0.31 · Purchase (P): 77,148 @ $0.30 · Purchase (P): 86,947 @ $0.32 · Purchase (P): 78,116 @ $0.31 · Purchase (P): 77,417 @ $0.30 | EDGAR |
| 2025-12-05 | 4 | Sandercock Colin — SVP, GENERAL COUNSEL | Grant/award (A): 30,000 (derivative) @ $0 · Grant/award (A): 70,000 (derivative) @ $0 | EDGAR |
| 2025-11-25 | 4 | Warren Lucinda — CHIEF BUSINESS OFFICER | Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2025-11-25 | 4 | Baker Daniel G. — CHIEF DEVELOPMENT OFFICER | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2025-10-02 | 4 | Azam Usman — CHIEF EXECUTIVE OFFICER, Director | Grant/award (A): 1,875,000 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Broadfoot Jill Marie — Director | Grant/award (A): 48,800 (derivative) @ $0 | EDGAR |
| 2025-03-25 | 4 | Millar Kerri-Ann — CHIEF FINANCIAL OFFICER | Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2025-03-25 | 4 | Baker Daniel G. — CHIEF DEVELOPMENT OFFICER | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2025-03-25 | 4 | Sandercock Colin — SVP, GENERAL COUNSEL | Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2025-03-25 | 4 | Warren Lucinda — CHIEF BUSINESS OFFICER | Grant/award (A): 250,000 (derivative) @ $0 | EDGAR |
| 2025-03-25 | 4 | Levisetti Matteo — Chief Medical Officer | Grant/award (A): 250,000 (derivative) @ $0 | EDGAR |
| 2025-03-25 | 4 | PASSERI DANIEL R — CHIEF EXECUTIVE OFFICER, Director | Grant/award (A): 450,000 (derivative) @ $0 | EDGAR |
| 2025-03-12 | 4 | Sarraf Pasha — Director | Grant/award (A): 48,800 (derivative) @ $0 | EDGAR |
Recent 8-K events — Cue Biopharma, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-14 | 8-K | 2.02 — Results of Operations and Financial Condition | EDGAR |
| 2026-08-03 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-07-10 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-03 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-02 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8.01 — Other Events | EDGAR |
| 2026-05-14 | 8-K | 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-01 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-22 | 8-K | 3.03 — Material Modification to Rights of Security Holders 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | EDGAR |
| 2026-04-13 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-04-07 | 8-K | 8.01 — Other Events | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=CUE returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →